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Abstract
Background: Financial recession mandated the introduction of harsh austerity measures. Health, and particularly
pharmaceuticals, constitute a significant part of public expenditure and as such they have been subject to significant
budget reduction and stringent policies. As a consequence of these measures, an increasing percentage of patients
resort to private sector for acquisition of their prescribed pharmaceuticals, due to exclusion of public health care
beneficiary status, reduction of breadth of national formularies, delays in reimbursement and excessive waiting times.
Affordability for pharmaceuticals in the private sector is of paramount importance since household disposable income
plummets and more people are prone to impoverishment. This is critical for branded products, whose active substance
and trademark are under patent protection, since no alternative options exist while their monopoly status imply that
their prices are high. The impact on affordability regarding access of patient to necessary pharmaceutical care has not
been documented in developed countries.
Methods: A laspeyer index was constructed to compare prices of branded pharmaceuticals and assess affordability, by
adjusting price index with Gross Domestic Product Purchase Power Parity per capita. Laspeyer index compares prices
based on weights, which in our study are the corresponding sales of products in Cyprus. Moreover, we define the
percentage of population that will face catastrophic pharmaceutical expenditure after acquisition of one product from
eight major and common therapeutic categories. We used data from five European recession countries: Italy, Portugal,
Spain, Greece and Cyprus, for 48 products which were selected based on sales.
Results: Cyprus displays the highest prices for pharmaceuticals. By adjusting for Gross Domestic Product Purchase
Power Parity per capita, affordability is worst for Cyprus and Portugal.
Conclusions: As more patients have to resort to private sector for provision of adequate and timely healthcare,
health agencies must reassess affordability of medicines and minimise catastrophic expenditure impact. Health
agencies should primarily try to enhance efficiency of the system and reduce waste, instead of resorting to blunt
budget reduction, which can demonstrate unpredictable consequences in public health.
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Key points
Financial recession exerts significant pressure on public
expenditure and disposable household income.
Crisis and austerity measures compromised the func-
tional capacity of public health sector and more people
have to resort to private health care sector for timely care.
Affordability of branded pharmaceuticals in the private
sector surfaces as a significant element, since it may im-
pede access of patients to necessary medicines.
Among 5 Mediterranean EU countries in recession, the
affordability for Cypriot patients is in the lowest position.
Governments should closely monitor affordability issue
of medicines and distribute financial burden equally
among all involved parties.
Background
In 2007 the worst financial crisis, after the Great Depres-
sion in the 30s, emerged and quickly escalated into a
global concern. In 2009, European Union’s Gross Do-
mestic Product (GDP) subsided by 4.9 % indicating the
impact across world’s second economy [1]. Reduced
GDP ensued to reduction of tax revenues, while un-
employment and fall of household disposable income in-
creased demand for counterpoising public resources in
health and social care.
Impaired funding capacity had to satisfy increased
needs. Health agencies tried to increase their efficiency
and adjust breadth, scope and depth of health care
coverage [2]. A general perception is that latter policies
are, by default, deprived of long-term vision and focus
on short-term savings [3]. Fiscal balance and adherence
to public expenditure target is acknowledged as the pri-
mary goal during fiscal crisis since these are the decisive
factors for disbursement of financial instalments by
international lenders. This unilateral focus on public ex-
penditure [4] explains why the majorities of measures
dealt with public sector, while private sector was largely
overlooked since expenditure is out-of-pocket and there-
fore not directly interrelated with fiscal deficit.
Private health expenditure during crisis is also massively
impaired. Primarily, crisis reduced household disposable
income, compromising ability to pay and signalling a shift
of patients to public health care sector. At the same time,
public health expenditure resources are reduced as un-
employment and salary reductions take their toll on tax in-
come. We must underline that crisis, both at macro
(unemployment) and micro level (job loss), is an independ-
ent risk factor for several health conditions which increases
health care demand and Health Agencies end up balancing
between the conflicting tasks of financing increased needs
with reduced funds. If more funds are allocated to health
sector, this will inflict losses on public expenditure and
consequently it will deteriorate fiscal deficit ultimately, this
will spare-out resources from other publicly funded
programs, such as social welfare and education, while fiscal
deficit was acknowledged as an independent health risk
factor.
In the pharmaceutical sector, changes have occurred
with a dramatically fast pace. Although the exact pattern
varies across countries, there are more similarities than
disparities and the broad framework resembles among
them (Table 1). This is expressed in increase of personal
contribution and copayment, exclusion of products from
formulary, monitoring of prescribing, introduction of
Health Technology Assessment (HTA), and reduction of
refill duration to avoid waste. Elasticity of income can
classify medicines as a necessity [5] and evidence from
previous financial crisis showed that, in general, con-
sumption of medicines was not compromised during
economic crisis.
During the 90’s crisis in Asia, the decline in consumption
of medicines lagged GDP decline [6]. The consumption of
medicines for chronic diseases recovered quicker than
overall consumption, while the consumption for acute
health conditions recovered slower than GDP. These find-
ings refer to low income countries, which demonstrate
inordinate pharmaceutical prices compared to average in-
come, pharmaceutical expenditure represents a significant
percentage of total health expenditure and, most import-
antly, health insurance coverage is not universal. In the
Baltics, crisis was associated with a significant reduction in
the sales of over-the-counter pharmaceutical products
(OTC-pharmaceutical products which can be dispensed
without a prescription), while among prescription products
only the consumption of pscyhoanaleptic products demon-
strated reduction [6]. European Health systems offer a uni-
versal health coverage, which renders a safety net for
patient through its prepayment mechanism for risk pool-
ing. A recent study among EU countries reported an
increase in pharmaceutical sales volumes almost in all of
them regardless fiscal position, while value of sales
declined, with a more pronounced effect in recession
counties, which is attributed to more frequent and steeper
price reduction [7].
Table 1 Importance of private sector during financial crisis
Reasons Countries affected
Exclusion of many patients
from public health coverage
Spain, Greece, Cyprus, Portugal
Extended freeze of inclusion of
new products in the formulary
Spain, Greece, Cyprus, Italy,
Portugal
Exclusion of several products
from formulary
Spain, Greece, Cyprus, Italy,
Portugal
Prolonged shortages of reimbursed
medicines
Spain, Greece, Italy, Portugal
Long waiting lists in the public sector
due to austerity measures (recruitment
freeze of health professionals)
Spain, Greece, Cyprus, Italy,
Portugal
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Despite universal access pattern of EU healthcare sys-
tems, it is anticipated that a steadily increasing number of
patients rely on out-of-pocket payment (private sector) for
their necessary health care [8] (Table 2). To begin with,
exclusion of many former beneficiaries from public health
coverage occurred, both direct and indirect. Direct exclu-
sion of beneficiaries was observed due to the detrimental
outcome of policies, which were primarily applied to tar-
get some of the causes of recession, such as tax evasion.
Specifically this led to exclusion of many unemployed
from public coverage as following:
– Unemployed Cypriots must have contributed to
social insurance for three years before they are
entitled to free medical care. Therefore, newly
recruited employees are not covered.
– Unemployed Spanish citizens over 26 are entitled
only to emergency care.
– Unemployed people in Greece are also excluded.
Moreover, sudden impoverishment and reduction of
household’s disposable income forced a significant per-
centage of patients in Greece to forfeit their health insur-
ance fees, in order to satisfy more urgent needs, such as
housing. In addition to the above, other traits of the post-
recession healthcare market, as formed by recession and
austerity measures, shift indirectly patients to private sec-
tor. This is induced by:
 Prolonged freeze of inclusion of new products in the
formulary therefore patients can procure the product
only through private sector.
 Exclusion of several former reimbursed products
from formularies due to reduction of their breath,
which leads to distortion of continuity of care and
forces patients to continue buying the product in
the private sector, and
 Prolonged shortages of reimbursed medicines.
Other cost-containment approaches include the reim-
bursement of only a single product from a broader thera-
peutic category, which is procured through tendering, an
aggressive pricing and reimbursement scheme. This leads
to significant savings for the buyer, since high and guaran-
teed estimated sales volume facilitates greater price reduc-
tion through enhanced competition. Nevertheless, this
may backfire in case patients do not respond or tolerate
the specific product. Under these circumstances, people
resort to the private sector and all costs incur patient. Fur-
thermore, in the broader health sector, long waiting lists,
ascribed to austerity measures, such as recruitment freeze
of health professionals further aggravate public health, for-
cing people to private sector, especially for acute condi-
tions and time sensitive health conditions.
Current literature lacks affordability studies on behalf of
private sectors patients, which is attributed to the theoret-
ical universal coverage that EU health system provide to all
EU citizens. Affordability is, to a certain extent, an ambigu-
ous term [9, 10]. It usually describes establishing and main-
taining an optimum (as perceived by the individual taking
into consideration contextual particularities of each coun-
try and socioeconomic environment) living standard,
which is compatible to an individual's income. Therefore,
affordability is intertwined with the income of each house-
hold, price of relevant product and exact description of
the “unreasonable financial burden”. Foremost, it is mas-
sively impaired when health expenditure exceeds 40 % of
the total income of the individual, and any health
expenditure higher than this, are considered to be cata-
strophic. For medicines alone, this percentage is 5 % [11].
The scope of this paper is to assess the impact of
financial recession on prices and affordability of branded




This study was performed from a Cyprus perspective,
using sales volume from Cyprus pharmaceutical market.
We selected the 100 top selling branded products in
value, which account for 42 % (value) of the total mar-
ket, in order to get a representative sample. Branded
products are defined as the pharmaceutical products,
whose active substance and trademark are under patent
protection and no generics can be registered. We
searched for the same products in the other countries,
price was estimated based on defined daily dose (DDD)
and, the final sample consists of 48 branded products in-
dicated for primary care conditions in Portugal, Spain,
Italy, Greece and Cyprus.
Sources
We used the official price lists of the five included coun-
tries. Moreover, personal communication with experts in
each county, through the Pharmaceutical Pricing and Reim-
bursement Initiative(PPRI1)—supported by World Health
Organization and Collaborating Centre for Pharmaceutical
Pricing and Reimbursement Policies- were conducted
for verification of data.
Selected countries
Criteria for inclusion of comparative countries were defined
in order to capture countries facing fiscal recession. Eligible
countries were defined as those that experience financial
recession, which is defined as two successive quarters of
negative growth in gross domestic product. Criteria for in-
clusion were delineated as following:
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Table 2 Cost-containment measures implemented by selected countries
Portugal Greece Spain Cyprus Italy




patients in Cyprus )
343 million euros (−11.7 %)
IN 2012
1 billion euro in 2012.
(from €5.4 billion in
2010 to an estimated
3.5 in 2012)
8.8 % reduction in 2011
pharmaceutical expenditure
for 2011
8.5 % Reduction for
2015
25.1 billion in 2012 to $23.5 billion in





Pharmacists Mark-up profit reduction Mark-up profit reduction
Introduction of Rebates/
clawback
Mark-up profit reduction Introduction of
regressive mark up
profit plus fee for
service
Mark –up profit reduction
Pricing 7 % average price cut on drugs 25 % temporary price
cuts reduction, Regular
Price interventions





Renegotiation of the prices of less effective
medicines
Up to 30 % price reduction
for medicines in 2010
6 % mandatory discount in retail
price for all reimbursed medicines
20–35 % price cut for some
generics products
7.5 % price cut for biologics
Generics Incentives for generic prescribing.
Priced 50 % below the RRP of the
reference product, or 25 % per




40 % of medicines
used in public hospitals
INN prescribing N/A 12.5 % reduction in the prices of generic.
Generic penetration is 20 % (volume).
(Royal Decree 16/2012)
Obligatory dispensing of the
cheapest generic version of a
drug.Pricing cannot exceed
40 % of the equivalent
branded product.
60 % of value of
prescribed products
must be generics
Prescribing INN prescribing INN prescribing INN prescribing INN prescribing only
in public sector
INN prescribing
Doctors have a personal
budget for pharmaceuticals
equals to 80 % of corresponding
last year’s period.
User Charges Increase of contribution 1 euro medical prescription
fee 0 %
1€ rate per prescription. Annual
cap independent on income
Pensioners: co-payment rate
10 % of Price with monthly cap
depending on income
Co-payment Increase (varying regional levels)
Tier A, 90 % of the public price of
the drug is reimbursed. This tier is




generic product is reimbursed
Changes in co-payment rates for
non-pensioners: 40, 50 or 60 %
depending on income. No cap
Tier B: 69 % of the public price is
reimbursed (essential drugs for
chronic diseases)
Tier C: 37 % of the public price is















Table 2 Cost-containment measures implemented by selected countries (Continued)
Tier D: 15 % of the public price
is reimbursed. (new medicines)
Reimbursement Delay of medicine’s reimbursement Delay of medicine’s
reimbursement
Dispensing of medicines for a
maximum period of 30 days.
(chronic conditions are exempted)
417 medicines indicated for minor
symptoms are excluded
Reimbursements prices for generic drugs
to the average European level.
Regular Revisions the list of reimbursable
pharmaceuticals
Efficiency gains Centralised hospital drug purchasing
system
Tendering Tendering HTA (Public sector
only)
Regulation of Length of stay Reduction
of hospital beds






Definition of admission criteria
Monitor of pharmaceuticals consumption
across regions
Strick controls over hospital budgets for
pharmaceuticals
Centralisation of procurement procedures
HTA electronic medical records
Pay-for-performance schemesHTAElectronic prescribing
Guidelines Increase of patients
assigned to GP
Industry Clawback Clawback Clawback N/A Pharmaceutical expenditure ceiling to13
percent of total health expenditure.
Overall pharmaceutical spending cannot
exceed 16 percent of health expenditure
[12].
Additionally 15 % rebate on products
marketed for more than 10 years but
with no equivalent generic or
biosimilar in the market
Cost Reduction Breadth Breadth Breadth Breadth Breadth
Scope Scope Scope Scope Scope
Depth of health coverage Depth of health coverage Depth of health coverage Depth of health
coverage














 Introduction of measures to cope with financial deficit
or gross debt, debt to GDP ratio of 60 %, and/or
 Adoption of Memorandum of Understanding on
specific economic policy conditionality (or economic
adjustment programme) with international lenders
(International Monetary Fund, European Central
Bank, European Commission –Troika) [8]
Comparative countries include Spain, Portugal, Greece
and Italy and we searched for official retail prices of the
same product across these countries. These countries are
also relevant for Cyprus since they are among the basket of
countries that Cyprus utilises for its external price referen-
cing. Ireland exited the memorandum in 2013, nevertheless
it was not included since pharmaceutical retail prices for
private patients are not explicitly defined and its inclusion
could have led to biased results [12].
A Laspeyer index was constructed from a Cyprus
perspective. Laspeyrer index allows weight of data only for
one participant, which in our case is Cyprus, and which
will be used as the reference country due to availability of
data. In this approach value and not price of basket prod-
ucts will define the significance of each product in Cyprus
health care setting, in the elaboration of the comparative
index. Laspeyer index captures in a more precise way the
uptake and relevance of each product in a specific setting.
Additionally, it depicts the significance in terms of budget
impact and as such, it is superior to a price index. In this
direction we used sales data from Cyprus private sector to
weight each product with its actual budget impact. The
use of retail price was preferred, in line with other author’s
approaches, since this is the cost incurred to the patient
[13, 14]. Moreover, ex-factory price is not applicable in
Cyprus. We searched through official pricelists, as per
2011, of competent authorities in aforementioned coun-
tries, for which we selected the identical package and
strength [15–19]. In case that the same package was not
available across sample countries, price per DDD was
assessed and the price was adjusted based on the rec-
ommended treatment duration (monthly for chronic
disease) according to the formula adopted by Pharma-
ceutical services. Nevertheless, all products were avail-
able in the same package and strength.
In order to assess affordability, we weighted our findings
on Gross Domestic Product (GDP) Purchasing Power Par-
ity (PPP) per capita, a preferred tool for cross-country price
comparisons [20, 21].
The second part of this study was performed to fur-
ther confirm our findings. We compare affordability with
impact of potential catastrophic pharmaceutical expend-
iture. We define the percentage of the population, that
it will face catastrophic pharmaceutical expenditure after
acquisition of one product from each major and common
therapeutic category. One medicine was selected from
each category, based on the prescribing pattern in Cyprus.
We included products for the following conditions: dia-
betes mellitus type II, osteoporosis, blood pressure, hyper-
cholesterolemia, asthma, dyspepsia (ulcer), depression and
osteoarthritis. Data were extracted from Eurostat and we
used minimum official wage of unskilled government
worker from each country. For the definition of the cata-
strophic expenditure we used the rate of 5 % of household
dispensable income, as per literature. We further analysed
data for diabetes, as robust epidemiological data exist for
this medical condition [22].
Results
The highest prices of private sector pharmaceuticals
were reported in Cyprus and the lowest in Greece. After
adjusting for GDP PPP per capita, Cyprus demonstrates
the highest prices, followed by Italy and Portugal in
the second and third place respectively (Table 3) (Fig. 1).
In order to assess our findings, we further verified them
by defining impoverishment percentage. We assessed the
impact of 8 products, one from each of the following
major therapeutic categories: diabetes mellitus type II,
hypercholesterolemia, hypertension, depression, dyspep-
sia, Asthma, osteoporosis, anti-inflammatory (Table 4).
Acquisition of one antidiabetic agent would be cata-
strophic for a 24 % of Italy’s diabetics patients, 25 % of
Greece’s, 19 % of Cyprus’ , 31 % of Spain’s and 23 % of
Portugal’s (Table 5). In addition to this, acquisition of
osteoporotic treatment would be financially catastrophic
for Portuguese and Cypriots, while the acquisition of a
combined medication for asthma would also be finan-
cially catastrophic for Portuguese and Cypriots patients.
Discussion
Access to necessary medicines is important and it becomes
crucial during recession, since recession was proved to be
an independent health risk factor leading to susceptibility
for several health conditions [23]. Moreover, inability to
finance current health needs does not cancel them out: it
rather shift these costs to a later and costlier stage. Health
agencies have implemented a series of measures to protect
vulnerable groups. These include increase of reimburse-
ment amount for pensioners as in Portugal, exception from
user charges for low—income people and people with ill-
nesses that would generate high out-of-pocket payments as
in Italy, and reduced and capped co-payment rate in Greece
and Spain. However, other policies shift patients to private
sector in an increasing trend. Exclusion of unemployed citi-
zens from public care as occurs in Spain, Greece and
Cyprus, urges for caution since their buying power is se-
verely compromised. Even indirectly, people are forced to
resort to the private sector since austerity measures provide
freeze of inclusion of new products in the formulary, reduc-
tion of formulary breadth, while shortages of reimbursed
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medicines take place regularly. Apparently, despite all as-
sumptions trying to explain shortages, the leading reason is
the accumulation of unpaid bills [24, 25]. In Greece, social
insurance fund owes pharmacists 400 million euros, which
directly impairs their liquidity and as result 203 products
were withdrawn from Greece; among them 25 did not have
generic available [26]. In Portugal, it is estimated that debts
to industry have mounted to 1 billion euro and payments
are on average 500 days due. Furthermore, in 2012, the
combined accumulated debt of Greece, Italy, Spain and
Portugal to the pharmaceutical industry exceeded 15 billion
euro [27]. Consequently, the industry is reluctant to supply
medicines due to accumulation of unpaid bills. As a result,
suppliers accept only cash payment, which in many cases is
not possible. This vicious circle end up at the patient, who
is expected to pay in cash and procure the prescribed medi-
cines as a private sector patient, an issue complicated by
impoverishment and high unemployment rates. Therefore,
eventhough, some products are officially reimbursed, are
available only for private purchase.
Moreover, countries deliberately delay reimbursement
process as a cost containment tool. In Portugal reim-
bursement period for some products may reach one
year, while reimbursment decisions for specialised medi-
cines may double that. Additionally, the approval of new
drugs has ground to a halt for 18 months and reim-
bursement decisions have been freezed for non-generics,
while the corresponding period for Greece spans up to
30 months. All aforementioned points attest to the fact
that a significant percentage of the population depends
on private sector for provision of healthcare.
Moreover, in Greece, persisting crisis has led to reduc-
tion of medicines intake by 33 % since patients cannot
afford them. A 28.4 % of Greek patients space out their
consumption due to affordability issues [28]. This was
aggravated by the fact that Greece has not updated its
positive list for 30 consecutive months, and all new
products were available only in the private sector. In
Italy, it’s estimated that the number of people that find it
hard to buy their prescribed medicines increased two
fold between 2006 and 2013 and the number of requests
for medicines rose by 57 % [29].
Affordability is also relevant for publicly reimbursed
products, for which patients incur a fixed amount or a
percentage on the product's retail price in the form of
co-payment. There are several reports entangling co-
payment with affordability issues and a strong and im-
mediate negative effect after increase of co-payment was
documented [30]. Even more alarmingly, co-payment is
more harmful for former good complying patients.
While affordability reached the peak of its popularity as
a demand proxy during financial crisis, several reports
prior to crisis indicate that a significant percentage of
patients (70.3 % in the UK and 66.5 % in Italy) expressed
concerns about the cost of medicines, in terms of co-
payment. Patients adopted several impromptu cost-
containment approaches, such as selective purchase of
prescribed medicines or delay or even avoidance to get
Fig. 1 Graph of prices, GDP PPP per capita and adjusted price index for GDP PPP per capita in the selected Countries
Table 3 Index of medicines’ prices and index adjusted by GDP PPP per capita
Italy Greece Cyprus Spain Portugal
Index of medicines prices 95,52 67,4 100 75,36 68,99
Index of medicines adjusted by GDP PPP per capita 85,54 71,75 100 69,27 80,71
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any prescribed medicines at all [31]. Most interestingly,
this study was performed in two high income European
countries, UK and Italy, which both operate universal
health coverage systems. Spain also experienced similar re-
duction in medicines’ consumption to a varying level across
regions, which can be attributed to sensitivity of patients to
new co-payment rates [32]. Therefore, we can speculate
that situation is currently aggravated due to recession, con-
sequent reduction of household expenditure and further
dissemination of cost-sharing practices.
In view of the above, it is imperative that health agencies
should try to explore other areas for cost containment and
increase of income revenue. In all recession countries, the
majorities of reforms that had to do with efficiency en-
hancement lagged expenditure cuts. Common practices
such as electronic prescribing, HTA and guidelines have
been applied at a later stage while cost reduction policies
preceded. This raises question about procrastination and/
or impotence of former health agencies to proactive apply
measures [33] and it also displays the message of fore-
thought policy making, especially during turbulent pe-
riods. Although, it is tempting to shift costs to patients,
either through exclusion of beneficiary status, reduction
of available products, or through disproportionate co-
payment, this can backlash by hindering access of patients
to necessary healthcare which can culminate in public
health risk. Therefore cost reduction policies should be
coupled with efficiency enhancement, eventhough the
logistic impact of latter measures is highly uncertain.
Cyprus is in the worst position among the five
assessed countries. The affordability of medicines, ad-
justed for GDP PPP per capita is the lowest among the 5
countries. Moreover, the acquisition of one product from
three major categories (each one at a time) would be
catastrophic for 19 % of its population. Cyprus, as one of
the latest countries to apply for a bail-out, still has not
implemented the magnitude of changes, as observed in
the other countries. This results to high prices in the
private sector, which given the impaired affordability of
patients, can be considered as a potential restrictive bar-
rier to pharmaceutical care. Moreover, the recent intro-
duction of a prescription fee (1 euro) furthers aggravates
current situation [34].
Medicines represent only a fraction of total health
costs. Therefore, total financial burden on households is
multiplied shall we include physician, laboratory and
hospital costs.
Coverage during crisis must be universal. If this is not
feasible, a safety net must be drawn for vulnerable
groups. Patient’s access to effective medicines must be
safeguarded at all costs. Private sector remains a realistic-
or the only- option for a significant proportion of the
population. Primarily, it should not be overlooked, under
the flawed assumption that health systems offer a univer-
sal and adequate coverage. Financial burden should be
equally distributed among involved parties, including
pharmaceutical industry, patients and pharmacists. Pricing
of pharmaceuticals is a step up process, spreading from
Table 5 Catastrophic health expenditure
Italy Greece Cyprus Spain Portugal
Percentage of population of each acquisition of one product could be assessed as exceeding the
threshold of catastrophic expenditure
24 % 25 % 19 % 31 % 23 %
Number of diabetics of which acquisition of one product could be assessed as exceeding the
threshold of catastrophic expenditure
975,000 150,000 15,000 992,000 230,000
Table 4 Affordability for eight major health conditions
Condition Products Strength Price (Eur) (Price calculated per monthly basis for each denoted strength )
Italy Greece Portugal Cyprus Spain
Dyspepsia Esomeprazolea 20 mg 7,08 10,81 8,8 18,63 6,3
Diabetes Januvia 100 mg 59,22 50,22 50,53 58,37 55,72
Osteoarthritis Etoricoxiba 90 mg 17,84 14,02 16,32 23,1 20,32
Blood pressure Candesartan 16 mg 11,95 12,36 22,62 28,8 25,76
Hypercholesterolemia Rosuvastatin 5 mg 22,49 11,27 17,01 28,74 18,9
Depression Escitaloprama 10 mg 24,97 13,23 11,52 15,39 16,66
Osteoporosis Zolendronic acidb 5 mg/100 ml 557,36 451,27 344,21 590,98 422,65
Asthma Salmeterol/Fluticasone 25/50 μg 41,22 34,39 36,15 41,33 39,6
Lowest monthly wage 992.4 [15] 878 565 870 748
Catastrophic expenditure threshold 942.8 834 536 826 710
aFor Esomeprazole, Etoricoxib and Escitalopram, the cost was calculated based on consumption for 28 days, thus calculating the cost of two packages
bFor Zolendronic acid, the monthly cost was calculated, since this product is administered yearly
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ex-factory to gross retail, for that reason agencies should
equally intervene on all stages of pricing. In some coun-
tries, such as Germany, wholesale price is only a small
fraction of the final price, due to immoderate mark-up
and pharmacist fee. In the majority of the cases, agencies
regulate wholesale prices, since these are the officially de-
fined prices and as a result fail to capture the magnitude
of the problem. Therefore, retail prices, which incorporate
general taxes as well that extend beyond pharmaceutical
policy, such as VAT, must be scrutinized and monitored
[35]. If deemed feasible, tax exemption must be consid-
ered as an alternative.
Innovative approaches must be introduced, targeting
chronic patients, such as supply of subsided products
through private distribution chain [36].
Conclusion
It is well documented that satisfactory health levels must
be considered as a goal to help a society overbear crisis
and not as a target after crisis. Therefore, belt-tightening
strategies should be adjoined with establishment of health
as a social investment, with long-term focus. Agencies
should proactively strive for efficiency instead of resorting
to easy healthcare budget cuts, which may impair access
of patients to the neccessary medicines. Access to afford-
able medicines must be safeguarded and affordability on
essential healthcare should be assessed frequently. A focus
on short-term financial gains is a myopic approach, which
may increase inequity in health therefore health agencies
should strive for long-term health and financial gains. Epi-
demiological studies must be carried out more frequently
in order to detect earlier any trends which may demon-
strate negative impact on public health. Since this is a
primarily financial crisis, unless its root causes, such as
corruption, bloated bureaucracy and tax evasion are
identified and eradicated, all measures targeting the
manifestations of the crisis will fail.
Limitations
A laspeyer index was utilised for this study. Laspeyer
index uses local weights of a specific setting (in our case
Cyprus) to create a comparative index. One drawback is
the possible failure to capture the exact patterns in other
countries, since it is assumed that other countries follow
the same pattern as Cyprus with regards to market share
of pharmaceuticals used in the study. This could be
erected as a barrier shall we compare countries with sig-
nificant social and economic span. Nevertheless, we do
not expect that significant deviations exist among
pharmaceutical markets of these five countries, at least




DDD: Defined daily dose; EU: European Union; HTA: Health Technology
Assessment; GDP: Gross domestic product; PPP: Purchasing power parity;
VAT: Value added tax.
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